{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-036870","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.533854+00:00","generated_at":"2026-05-15T08:23:14.442516+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Theravance settles YUPELRI patent suit; generic license start April 23, 2039","bullets":["Settlement with Mankind Pharma resolves Hatch-Waxman litigation over YUPELRI (revefenacin) ANDA.","Royalty-free license granted for generic version on or after April 23, 2039, subject to customary exceptions.","All pending Hatch-Waxman litigation relating to YUPELRI now resolved; settlement subject to DOJ/FTC review.","Involves patents 11,484,531, 12,048,692 and 12,285,417; parties include Theravance subsidiaries and Mylan."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-036870","json":"https://secwatch.observer/filing/0001104659-26-036870.json","markdown":"https://secwatch.observer/filing/0001104659-26-036870.md","text":"https://secwatch.observer/filing/0001104659-26-036870.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926036870/0001104659-26-036870-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926036870/tm2610626d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:23:14.442516+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}